Additional file 1: Table S1. of SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial
Christoph Rochlitz, Ralph C. Winterhalder(Luzerner Kantonsspital), Daniel Rauch(Washington University in St. Louis), Kyung-Jae Na(Novartis (Switzerland)), Andreas Trojan(Immunologie-Zentrum Zürich), Roger von Moos(Kantonsspital Graubünden), Tamara Rordorf(Institut Gustave Roussy), Ursula Hasler-Strub(Kantonsspital Graubünden), Sandro Anchisi(Hôpital du Valais), Khalil Zaman, Richard Cathomas(Kantonsspital Graubünden), Marc Küng(HFR Freiburg Kantonsspital), Martin Bigler(Swiss Group For Clinical Cancer Research), Jürg Bernhard(International Breast Cancer Study Group), Klazien Matter-Walstra, Andreas Wicki, Marcus Vetter, Markus Borner, Thomas Ruhstaller(University Hospital Bonn), Andreas Müller, Daniela Bärtschi(Swiss Group For Clinical Cancer Research)
Cited by 0
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines
|European Urology|2020|2.2k